[go: up one dir, main page]

WO2008143880A3 - Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury - Google Patents

Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury Download PDF

Info

Publication number
WO2008143880A3
WO2008143880A3 PCT/US2008/006158 US2008006158W WO2008143880A3 WO 2008143880 A3 WO2008143880 A3 WO 2008143880A3 US 2008006158 W US2008006158 W US 2008006158W WO 2008143880 A3 WO2008143880 A3 WO 2008143880A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain injury
traumatic brain
bryologs
bryostatins
therapeutic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/006158
Other languages
French (fr)
Other versions
WO2008143880A8 (en
WO2008143880A2 (en
Inventor
Ofer Zohar
Daniel L Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/001755 external-priority patent/WO2008100449A2/en
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Publication of WO2008143880A2 publication Critical patent/WO2008143880A2/en
Publication of WO2008143880A3 publication Critical patent/WO2008143880A3/en
Publication of WO2008143880A8 publication Critical patent/WO2008143880A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat traumatic brain injury. Specifically, the present invention provides methods of treating traumatic brain injury comprising the steps of identifying a subject having suffered a traumatic brain injury and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of traumatic brain injury.
PCT/US2008/006158 2007-05-24 2008-05-14 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury Ceased WO2008143880A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92466207P 2007-05-24 2007-05-24
US60/924,662 2007-05-24
PCT/US2008/001755 WO2008100449A2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
USPCT/US2008/001755 2008-02-11
US12/068,742 2008-02-11
US12/068,742 US9974832B2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Publications (3)

Publication Number Publication Date
WO2008143880A2 WO2008143880A2 (en) 2008-11-27
WO2008143880A3 true WO2008143880A3 (en) 2009-06-04
WO2008143880A8 WO2008143880A8 (en) 2009-08-13

Family

ID=40091420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006158 Ceased WO2008143880A2 (en) 2007-05-24 2008-05-14 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury

Country Status (1)

Country Link
WO (1) WO2008143880A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027687A1 (en) 2010-07-08 2012-02-02 Alkon Daniel L Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke
RU2470302C1 (en) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Method of predicting cognitive disorders in remote period of craniocerebral trauma
WO2014145316A1 (en) 2013-03-15 2014-09-18 Alkon Daniel L Methods for identifying neuroprotective pkc activators
WO2023133230A1 (en) * 2022-01-08 2023-07-13 Sohn Joanna Monoacetyldiglycerides (plag) as a mitigating agent for traumatic brain injury and ischemia-reperfusion injury

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
WO2004047857A1 (en) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Use of fgf-18 in the diagnosis and treatment of memory disorders
WO2006031337A2 (en) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement
WO2008013573A1 (en) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
WO2008100449A2 (en) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
WO2004047857A1 (en) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Use of fgf-18 in the diagnosis and treatment of memory disorders
WO2006031337A2 (en) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement
WO2008013573A1 (en) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
WO2008100449A2 (en) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Also Published As

Publication number Publication date
WO2008143880A8 (en) 2009-08-13
WO2008143880A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008100449A3 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
Sarlak et al. Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration
Ou et al. Transcriptional regulation of brain-derived neurotrophic factor in the amygdala during consolidation of fear memory
Dahmani et al. Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation
BR0316004A (en) Pharmaceutical composition comprising a cdk and gemcitabine inhibitor
ATE418991T1 (en) METHOD FOR TREATING CARDIAC RHYTHM DISORDERS USING AN A1 ADENOSINE AGONIST TOGETHER WITH A BETA BLOCKER
Bersani et al. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
BR0312933A (en) Pharmaceutical composition, pharmaceutical dosage unit, method for treating one or more diseases associated with a vascular condition, and therapeutic combination.
WO2007137247A3 (en) Treatment for depressive disorders
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
WO2008143880A8 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
WO2006099015A3 (en) Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
Nori et al. Increased nerve growth factor signaling in sensory neurons of early diabetic rats is corrected by electroacupuncture
Bierl et al. Increased NGF proforms in aged sympathetic neurons and their targets
WO2008100450A3 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
TW200621788A (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Iε
Miyazato et al. Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat
BRPI0507482A (en) combination of (a) a dna topoisomerase inhibitor and (b) a iap inhibitor
NO20071466L (en) 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogues as inhibitors of casein kinase IU
WO2005041857A3 (en) Bone morphogenetic protein (bmp) 2a and uses thereof
Wanner et al. Muscarinic receptors within the ventromedial hypothalamic nuclei modulate metabolic rate during physical exercise
BR0316029A (en) Combination
HUE033997T2 (en) Fluor-9-methyl-beta-carbolines
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2